Avidekel oil reduced agitation significantly more than placebo: 60% vs. 30% achieved a ≥4-point reduction in the Cohen-Mansfield Agitation Inventory Score (p=0.03), with good safety.
RCT (n=60, mean age 79,4 years, 60% women) on CBD-rich oil (30% CBD/1% THC) vs. placebo for behavioral disturbances in dementia over 16 weeks. Primary endpoint (CMAI reduction ≥4 points): 60,0% (24/40) under active treatment vs. 30,0% (6/20) under placebo (χ²=4,80, p=0,03). CMAI reduction ≥8 points: 50% vs. 15% (χ²=6,42, p=0,011). ANOVA showed significantly greater improvement at week 14 and 16 (F=3,18, p=0,02). Good tolerability, no significant differences in adverse events.
The third of four GRADE levels, the effect estimate is probably reliable.
The impediment to action advances action.